Rating To Observe: Bellicum Pharma (BLCM) Moves On Ladenburg Thalmann Initiation

November 30, 2016 - By Ruchi Gupta

Rating To Observe: Bellicum Pharma (BLCM) Moves On Ladenburg Thalmann Initiation

How Ladenburg Thalmann Rates Bellicum Pharma (BLCM)

Ladenburg Thalmann initiated its coverage on Bellicum Pharma (BLCM), today Wednesday morning. The research firm finds the stock of Bellicum Pharma (BLCM) attractive and has given it “Buy” rating.

About 52,323 shares traded hands. Bellicum Pharmaceuticals Inc (BLCM) has risen 83.70% since April 27, 2016 and is uptrending. It has outperformed by 78.47% the S&P500.

Analysts await Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to report earnings on March, 13. They expect $-0.61 earnings per share, up 3.17% or $0.02 from last year’s $-0.63 per share. After $-0.66 actual earnings per share reported by Bellicum Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -7.58% EPS growth.

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $522.93 million. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. It currently has negative earnings. The Firm uses its chemical induction of dimerization technology platform to engineer and then control components of the immune system.

According to Zacks Investment Research, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.”

BLCM Company Profile

Bellicum Pharmaceuticals, Inc., incorporated on July 14, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Firm uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Firm is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. The Company’s CID technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

More notable recent Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) news were published by: Marketwatch.com which released: “Bellicum Pharmaceuticals upgraded to buy from neutral at Citigroup” on December 18, 2014, also Fool.com with their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Juno Therapeutics, Inc.” published on June 26, 2016, Fool.com published: “Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.” on October 18, 2016. More interesting news about Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) were released by: Fool.com and their article: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. Celldex Therapeutics” published on August 03, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Bellicum Pharmaceuticals Inc.BLCM” with publication date: December 13, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>